Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Operating Leases (2022 - 2026)

Biodesix filings provide 5 years of Operating Leases readings, the most recent being $23.7 million for Q1 2026.

  • On a quarterly basis, Operating Leases fell 3.31% to $23.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $23.7 million, a 3.31% decrease, with the full-year FY2025 number at $24.0 million, down 3.18% from a year prior.
  • Operating Leases hit $23.7 million in Q1 2026 for Biodesix, down from $24.0 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $25.5 million in Q2 2024 to a low of $1.2 million in Q1 2022.
  • Median Operating Leases over the past 5 years was $24.1 million (2025), compared with a mean of $18.5 million.
  • Biggest five-year swings in Operating Leases: surged 922.85% in 2023 and later dropped 5.37% in 2025.
  • Biodesix's Operating Leases stood at $5.3 million in 2022, then skyrocketed by 378.93% to $25.2 million in 2023, then dropped by 1.33% to $24.8 million in 2024, then dropped by 3.18% to $24.0 million in 2025, then dropped by 1.54% to $23.7 million in 2026.
  • The last three reported values for Operating Leases were $23.7 million (Q1 2026), $24.0 million (Q4 2025), and $24.4 million (Q3 2025) per Business Quant data.